Search in the Abstract Database

Abstracts Search 2017

* = Presenting author

OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease

Sandborn W.J.1, Cyrille M.2, Berner Hansen M.3, Feagan B.G.4, Loftus Jr. E.V.5, Vermeire S.6, Cruz M.L.2, Mo M.2, Sullivan B.A.2, Reinisch W.*7

1University of California San Diego, La Jolla, United States 2Amgen Inc., Thousand Oaks, United States 3University of Copenhagen, Copenhagen, Denmark 4Robarts Research Institute, University of Western Ontario, London, Canada 5Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States 6University Hospitals Leuven, Leuven, Belgium 7Medical University Vienna, Vienna, Austria

Background

Adhesion molecule α4β7 is a validated treatment target in inflammatory bowel diseases. We evaluated abrilumab, a fully human monoclonal antibody against α4β7, in patients with moderate to severe Crohn's disease (CD).

Methods

This phase 2b, randomised, multi-centre, double-blind, placebo (Pbo)-controlled study enrolled patients aged 18–65 years with moderate to severe CD (CDAI score 220–450) and evidence of active inflammation (by endoscopic evaluation, or elevated C-reactive protein or fecal calprotectin). In addition, patients must have had inadequate or loss of response or intolerance to immunosuppressives, TNF antagonists, or corticosteroids. Eligible patients were randomised to receive Pbo or abrilumab (21 or 70 mg) SC on day 1, weeks 2 and 4, and every 4 weeks (Q4W) for up to 24 weeks, or one dose of abrilumab 210 mg SC on day 1. The primary endpoint was CDAI remission (score <150) at week 8. Key secondary endpoints were remission at week 12 and CDAI response (reduction from baseline of ≥100) at weeks 8 and 12. CD4+ T cell subsets were enumerated and α4β7 receptor occupancy was measured in a subgroup of patients.

Results

This study enrolled 249 patients. Final randomisation allocation was affected by a systematic misalignment in investigational product, resulting in 98, 26, 84, and 41 patients in the Pbo, 21 mg Q4W, 70 mg Q4W, and 210 mg treatment groups, respectively. The study blind and randomisation were intact. Baseline demographics were similar. Statistically significant improvement was not achieved between the abrilumab 70 mg Q4W and Pbo arms for the primary endpoint (p=0.76 vs Pbo) (Table). However, higher rates of remission and response were observed in the active treatment arms at week 12, particularly in patients with prior failure of TNF antagonists assigned to the 210 mg abrilumab group. Maximal reduction of free α4β7 on naïve CD4+ T cells in the peripheral blood was sustained from the first measurement at week 2 to week 8 for all dose groups, and through week 12 for the 21 mg Q4W and 70 mg Q4W groups. Abrilumab induced a significant post-dose increase in α4β7-high central memory CD4+ T cell counts between baseline and week 8. Adverse events were similar among treatment groups through week 24, with no cases of PML or deaths. No patients developed neutralizing antibodies to abrilumab.

Conclusion

Although the primary endpoint was not met, beneficial effects of abrilumab were observed for remission and response rates. There was no safety imbalance compared with Pbo.

Amgen and AstraZeneca/MedImmune sponsored this study.